Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Diego Pilati & Kenneth A. Howard. (2020) Albumin-based drug designs for pharmacokinetic modulation. Expert Opinion on Drug Metabolism & Toxicology 16:9, pages 783-795.
Read now
Read now
L. Østergaard, Christian S. Frandsen & S. Madsbad. (2016) Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Review of Clinical Pharmacology 9:2, pages 241-265.
Read now
Read now
Darrell Sleep. (2015) Albumin and its application in drug delivery. Expert Opinion on Drug Delivery 12:5, pages 793-812.
Read now
Read now
Articles from other publishers (4)
Seyed Ebrahim Alavi, Peter J. Cabot & Peter M. Moyle. (2019) Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency. Molecular Pharmaceutics 16:6, pages 2278-2295.
Crossref
Crossref
Sivanandy Palanisamy, Emily Yien, Ling Shi, Low Si, See Qi, Laura Ling, Teng Lun & Yap Chen. (2018) Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients. Pharmacy 6:3, pages 57.
Crossref
Crossref
Yun Wan, Xi Bao, Jiabao Huang, Xiangyu Zhang, Wenjuan Liu, Qiaoli Cui, Dongdong Jiang, Zhihong Wang, Rui Liu & Qinghua Wang. (2017) Novel GLP-1 Analog Supaglutide Reduces HFD-Induced Obesity Associated with Increased Ucp-1 in White Adipose Tissue in Mice. Frontiers in Physiology 8.
Crossref
Crossref
M. M. Smits, L. Tonneijck, M. H. A. Muskiet, M. H. H. Kramer, D. L. Cahen & D. H. van Raalte. (2016) Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas. Diabetes, Obesity and Metabolism 18:3, pages 224-235.
Crossref
Crossref